Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
0(0%)
Results Posted
22%(2 trials)
Terminated
3(23%)

Phase Distribution

Ph phase_1
7
54%
Ph phase_3
1
8%
Ph phase_2
5
38%

Phase Distribution

7

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
7(53.8%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

69.2%

9 of 13 finished

Non-Completion Rate

30.8%

4 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(4)

Detailed Status

Completed9
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (53.8%)
Phase 25 (38.5%)
Phase 31 (7.7%)

Trials by Status

terminated323%
completed969%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_2

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

NCT01186861
completedphase_2

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NCT01221077
completedphase_1

Study of Continuous OSI-906 Dosing

NCT00514007
completedphase_1

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

NCT00739453
completedphase_1

Study of Intermittent OSI-906 Dosing

NCT00514306
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01186861Phase 2

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Completed
NCT01221077Phase 2

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Completed
NCT00514007Phase 1

Study of Continuous OSI-906 Dosing

Completed
NCT00739453Phase 1

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Completed
NCT00514306Phase 1

Study of Intermittent OSI-906 Dosing

Completed
NCT01101906Phase 2

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Terminated
NCT00889382Phase 1

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Completed
NCT00924989Phase 3

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Completed
NCT01529684Phase 1

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

Completed
NCT01154335Phase 1

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Completed
NCT01016860Phase 1

OSI-906 and Irinotecan in Patients With Advanced Cancer

Terminated
NCT01427205Phase 2

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Withdrawn
NCT01205685Phase 2

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Terminated

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13